Evidence map›Paper›PMID 37854861›Full record

ArticleOncology letters2023

Solamargine induces apoptosis of human renal carcinoma cells via downregulating phosphorylated STAT3 expression.

Shuaishuai Huang, Minyi Sun, Yu Ren, Ting Luo, Xue Wang, Guobin Weng, Dong Cen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Solamargine inhibited the progression of non-small cell lung cancerEuropean journal of histochemistry : EJH · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shuaishuai HuangLaboratory of Renal Carcinoma, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Minyi SunLaboratory of Renal Carcinoma, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Yu RenLaboratory of Renal Carcinoma, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Ting LuoDepartment of Medical Laboratory, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Xue WangLaboratory of Renal Carcinoma, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Guobin WengLaboratory of Renal Carcinoma, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Dong CenDepartment of Medical Laboratory, Ningbo Yinzhou No. 2 Hospital, Urology and Nephrology Institute of Ningbo University, Ningbo, Zhejiang 315100, P.R. China.
Ningbo No. 2 Hospital · CNNingbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solamargine (SM), an active compound derived from

Indexed as

apoptosishuman renal carcinomasolamargineSTAT3viability

Identifiers

PMID37854861
PMCPMC10579987
OpenAlexW4387135693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.